SPH: Shanghai Pharma Forms $250 Million China Antibody JV with Russia's Biocad

Shanghai Pharmaceuticals formed a JV with Russian biopharma Biocad that will include an initial investment of $250 million and is expected to lead to a $2.8 billion capitalization. The JV will develop six Biocad monoclonal antibodies targeting cancer and a...